|

Performance of Spectral CT-scan in Patients With Metastatic Colorectal Cancer: a Prospective Multicentre Study

RECRUITINGSponsored by Centre Hospitalier Universitaire de Saint Etienne
Actively Recruiting
SponsorCentre Hospitalier Universitaire de Saint Etienne
Started2023-06-07
Est. completion2025-01
Eligibility
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06024837

Summary

Spectral CT is a rapidly expanding imaging modality that allows a reduction in iodine dose and irradiation compared to conventional scanning. It uses the difference in attenuation of the material according to the two different energy levels of the incident x-ray beams. The dual-energy scanner has a wide range of clinical applications, particularly in abdominal imaging.

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

* Patients followed for colorectal cancer with synchronous or metachronous liver metastases and/or peritoneal carcinosis
* Patients with a curative surgical resection plan

Exclusion Criteria:

* Patients with non-metastatic colorectal cancer
* Patients treated with chemotherapy without surgical plans
* Patients with colorectal cancer with extra-hepatic and extra-peritoneal metastases alone (e.g. lung, bone)

Conditions4

CancerColo-rectal CancerLiver CancerLiver Disease

Browse More Trials

Cancer trialsLiver Disease trialsLiver Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.